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Structural and Functional Insights into the Human Pneumoviruses 
Glycoprotein Domain: Key Components for Vaccine Development
Introduction to Human Pneumoviruses
The Human orthopneumovirus (HRSV) and the Human metapneumovirus (HMPV) (1) are the major causative agents of
acute respiratory infections mainly within the paediatric population (<2 years of age). Both belong to the Pneumoviridae
family and share genomic, structural and functional similarities [Figure 1]. Both show global distribution, with a clear
pattern of seasonality extending from winter to spring months.
OBJECTIVES: the purpose of this study is to review HRSV and HMPV viral transmembrane proteins biology, structure
and function. In addition, the glycoproteins antigenicity, viral strategies of immune evasion and the current and futue
challenges of vaccine development wants to be described.
METHODOLOGY: for the elaboration of this project several articles, reports and reviews have been consulted. Unless
specifically mentioned, figures were elaborated with Microsoft® PowerPoint or PyMol Molecular Graphics System v2.1.
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Major Human Pneumoviruses Surface Glycoproteins Initial phases of infection are directed by the attachment (G) and fusion (F) glycoproteins. The G glycoprotein targets the HSPGs and CX3CR1 cellreceptors. However, it is non-essential for viral infectivity. By contrast, the F glycoprotein is essential for infectivity and suffers a major refolding
event upon entry in which the Fusion Peptide (FP) found at the F1 subunit is extruded promoting membrane fusion. Moreover, viral attachment,
in absence of the G protein, might be carried out by F protein. While the F glycoprotein remains highly conserved in sequence, the G
glycoprotein is highly variable, mostly in its mucin-like domains. A soluble G protein (sG) acting as an antibody-decoy has also been identified.
Figure 1 – HRSV and HMPV viral genome organization.
Both human pneumoviruses highly resemble each other and exhibit a linear negative-sensed (-) single stranded RNA genome of 13kb
(HMPV) or 15kb (HRSV) in length. The HRSV genome has two unique non-structural genes (NS1/NS2) at the leader sequence of RNA.
The nucleoprotein (N), phosphoprotein (P), Matrix (M) and polymerase (L) genes organization is shared. Differences are found in
organization of the small hydrophobic (SH), Fusion (F), Attachment (G) and M2 genes.
Figure 2 – Diagram of the HRSV-F gene and structural representation of the HRSV-F glycoprotein in pre- and post-fusion conformation.
(A) The signal peptide (SP) induces the translocation of the F protein towards the cell membrane. Furin-protease cleavage sites are indicated
in red, surrounding Pep27. F2 and F1 subunits are formed and linked by disulfide bonds (C-C) between cysteines (*), tridimensionaly
represented by grey bubbles. (B) Representation of the HRSV pre-fusion (left - PDB: 5TOJ) and post-fusion (right - PDB: 3RRR) monomers and
trimers has been assessed using Pymol Molecular Graphics System v2.1 (Schrödinger, LLC, NY, USA). Major refolding of the pre-fusion
conformation into the post-fusion state occurs in which the F1 C-term and F1 N-term regions are extruded, permitting the insertion of the
fusion peptide (FP) into the target cell, enabling fusion. HR= Heptad Repeat TM= transmembrane domain. CT= cytoplasmic domain.
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Figure 3 – Diagram of HRSV-G gene and structural representation of the HRSV-G glycoprotein.
(A) Three main unglycosylated regions consisting of cytoplasmic, transmembrane and the central conserved domains are found in HRSV-G
protein. Two highly-variable and glycosylated mucin-like regions (I - II), surround the central conserved domain that forms an unglycosylated
cysteine noose. Cysteines involved in the formation of it are represented by the asterisk (*) symbol. The heparin binding domain and the
CXC3-motif bind to the cell receptors heparin sulfate proteoglycans and CX3CR1 respectively. (B) Complex N-linked (yellow) and simple the
O-linked (grey) glycans decorate the protein, illustrating the size of the glycosylated G form in comparison with its backbone sequence.
Methionine-48 (Met48) serves as the start codon for the sG protein. Tridimensional representation of the HRSV-G protein was performed by
McLellan et al 2013 (2).
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Figure 5 – Antigenic Shielding explained by differences
of size and volume between HRSV glycoproteins.
The G protein due to its massive surface glycosylation,
which confers great volume (25nm height) and mass to
the protein, hinders the neutralizing antibodies binding
to the pre-fusion (13nm) and post-fusion (17nm)
conformations, both smaller in size. It exhibits a
shielding function preventing the recognition of the F
glycoprotein epitopes by neutralizing antibodies. This
evasive mechanism may be an important drawback for
developing vaccines against these pneumoviruses, as
the antibodies generated after vaccination may not
reach its target nor neutralize the virus .
Figure 4 – Tridimensional representation of neutralizing antibodies bound
to antigenic sites in HRSV-F glycoprotein.
Antigenic sites I, II, IV and Ø are found on HRSV-F. Sites II and IV are also
present in the post-fusion conformation whereas antigenic site Ø (D25 -
red) remains exclusive of the pre-fusion state. The strain-dependant
antigenic site I is situated in the F1 subunit. Antigenic site II is the binding
site of motavizumab (orange). The MPE8 antibody (green) cross-competes
with motavizumab for binding to pre-fusion HRSV-F state, partially
overlapping antigenic site II. MPE8 site is highly-conserved and can
neutralize both HRSV and HMPV. Finally, 101F antibody (purple) binds the
antigenic site IV. These neutralizing antibodies prevent the fusion of viral
and cell membranes. Illustration performed by McLellan et al. 2015 (3).
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Target populations who might benefit from a HRSV vaccine are: infants <6 months, children >6 months,
pregnant women and the elderly (>65 years). The main neutralizing determinant on the HRSV virion is the
HRSV-F glycoprotein which is also highly conserved in sequence, thus most vaccine approaches are based
on it. Live-attenuated vaccines are also being developed but, ensuring the balance between the virulence
of the vaccine strain and the immunogenicity elicited is an arduous task and often the innocuity of the
vaccine is questioned. No vaccines are currently available for HRSV nor HMPV.
Figure 6 – Overview of HRSV treatment development. General overview of HRSV vaccine (A), immunoglobulins (B) and
antiviral (C) treatment development. Company name and product are given and classified by development stage (phase I-III
and marketed). Only, palivizumab and the antiviral drug ribavirin have been licensed for administration. Image up to date
through May 2018. Data collected from U.S. National Library of Medicine - Clinical Trials website (www.clinicaltrials.gov).
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Overall, since F protein is relatively conserved in sequence, its surface location, its essentiality for viral entry, its immunogenicity and, the fact that has the ability to elicit a protective immunity; make the F protein an
ideal target for neutralizing antibodies and a promising candidate for vaccine development. By contrast, the G protein is another major antibody target, but due to its high variability and glycan decoration makes it not a
suitable candidate for prophylactic treatment development. Nonetheless, several promising vaccines are currently being developed and one or both of the main glycoproteins are included in most vaccine modalities.
